FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting.”
Pressure BioSciences, Inc. (OTCQB: PBIO) announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples. This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.
Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report that between 1950 and 2017, there were a total of 359 new diseases and injuries added to the fatal and non-fatal list of conditions. Some of the most common cases include cancer, heart conditions, stroke, respiratory infections, lung diseases, Alzheimer’s, diabetes, and kidney diseases. While some of these conditions are unpreventable, conditions such as cancer and heart issues can be resolved or their spread slowed with innovative treatment and medicine. For instance, patients suffering from cancer typically undergo therapies such as chemotherapy or radiotherapy. Chemotherapy and radiotherapy are two of the most common cancer treatments and are aimed towards prolonging life expectancy, controlling or eradicating malignant cells. And despite its effectiveness, biotechnology companies are continuing to develop new and innovative treatments such as targeted therapies or personalized treatments. Nonetheless, while biotechnology companies are progressing within the industry, each year more and more cases of medical conditions are emerging throughout the world. However, some regions tend to have a more developed healthcare system and can immediately address the needs of their patients. On the other hand, underdeveloped regions typically lack adequate access to proper healthcare, which ultimately results in a large number of fatalities and untreated people. The IHME said in 2017 that regions such as Canada, Japan, Australia, and western Europe had the highest life expectancies. Meanwhile, the central and southern regions in Africa had the lowest life expectancies. And despite the disparities between the developed and underdeveloped regions, biotechnology companies are slowly moving towards addressing the overall global matter. According to data compiled by Global Market Insights, the global biotechnology market was valued at USD 399.4 Billion in 2017 and is expected to witness a CAGR of 9.9% from 2018 to 2024.
Customarily, most cancer patients receive similar treatment depending on their specific type of cancer and the stage progression. However, researchers began to notice that treatments were more effective for some people, while others received experienced little to no response. As such, researchers realized that genetics differences in each patient can influence how they respond to the treatment. For instance, a patient who can process medicine much faster than others would likely require a higher dose of medicine for it to be effective. Moreover, some patients experience severe side effects from specific cancer drugs, making the process unbearable. And in certain instances, doctors will either prescribe an additional medicine or lower the dosage to reduce the painful side effects. Overall, the evolution of personalized treatments has completely reshaped how medical practitioners approach cancer therapy. Notably, researchers have begun to collect tissue samples in order to search for and better understand potential cancer biomarkers. Specifically, formalin-fixed paraffin-embedded (FFPE) and fresh frozen biopsy tissue samples have become widely practiced methods in clinical preservation. Generally, researchers use these tissues to search for specific proteins which can then be used as a diagnosis to indicate which cancer drugs would be the most effective, according to Biochain. Furthermore, biotechnology researchers can accelerate discoveries of new therapies and drugs that can be used towards curing or slowing cancers. “We have yet to realize the full potential of precision medicine, but we are making significant headway,” said Eva Kiesler, former Senior Science Editor at Memorial Sloan-Kettering Cancer Center, and Meredith Begley, Health and Medical writer at Memorial Sloan-Kettering Cancer Center. “Options for many people with cancer have dramatically improved through targeted therapies that reverse the effects of specific gene mutations in their tumor cells.”
For more information, please visit: Pressure Biosciences, Inc.
For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.